HomeFile

File

View Category
Coronary disease

Provisional Angioplasty in Left Main: What MSA Values Should We Target?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) represents one of the most...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

Predilatation in Self-Expanding Valves

TAVI has become the treatment of choice in specific scenarios. However, predilatation (PRD) remains a matter of...
Dr. Carlos Fava -
Learn More
Acute coronary syndromes

Flow Protocols in VA-ECMO: Impact on PCWP in Cardiogenic Shock

The use of peripheral femoro-femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO) has globally consolidated and is the...
Dr. Omar Tupayachi -
Learn More
Other

Tricuspid Regurgitation, TriBicaval Registry

Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery...
Dr. Carlos Fava -
Learn More
Coronary disease

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary...
Dr. Andrés Rodríguez -
Learn More
Mitral valve

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...
Dr. Carlos Fava -
Learn More
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...
Dr. Omar Tupayachi -
Learn More